Merck said worldwide sales for Q3 2024 were $16.7 billion, up 4% from the year-earlier quarter, and up 7% excluding the impact of foreign exchange. KEYTRUDA sales rose 17% to $7.4 billion.

1. 01

   Merck said worldwide sales for Q3 2024 were $16.7 billion, up 4% from the year-earlier quarter, and up 7% excluding the impact of foreign exchange. KEYTRUDA sales rose 17% to $7.4 billion.

2. 02

   The company said GAAP EPS for Q3 was $1.24 and Non-GAAP EPS was $1.57, and that both included a net charge of $0.79 per share related to certain business development transactions. GAAP EPS for the year-earlier quarter was $1.86.

3. 03

   The company said R&D expenses for Q3 were $5.9 billion, up 77% from the year-earlier quarter. It cited a charge of $1.35 billion for the acquisition of EyeBio, a related development milestone charge of $100 million, and a charge of $750 million to acquire CN201 (MK-1045) from Curon as factors.

4. 04

   The company narrowed its full-year 2024 worldwide sales outlook to $63.6 billion to $64.1 billion and set its Non-GAAP EPS outlook at $7.72 to $7.77. Its prior outlook was sales of $63.4 billion to $64.4 billion and Non-GAAP EPS of $7.94 to $8.04.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.